These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

692 related items for PubMed ID: 19898179

  • 1. Intravitreal bevacizumab for choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome.
    Ehrlich R, Ciulla TA, Maturi R, Kheradiya NS, Hrisomalos N, Shulman S, Guess MG, Coyle E, Harris A.
    Retina; 2009; 29(10):1418-23. PubMed ID: 19898179
    [Abstract] [Full Text] [Related]

  • 2. Intravitreal bevacizumab for choroidal neovascularization in ocular histoplasmosis.
    Schadlu R, Blinder KJ, Shah GK, Holekamp NM, Thomas MA, Grand MG, Engelbrecht NE, Apte RS, Joseph DP, Prasad AG, Smith BT, Sheybani A.
    Am J Ophthalmol; 2008 May; 145(5):875-8. PubMed ID: 18321466
    [Abstract] [Full Text] [Related]

  • 3. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
    Chan WM, Lai TY, Liu DT, Lam DS.
    Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
    [Abstract] [Full Text] [Related]

  • 4. Long-term results of intravitreal bevacizumab injection for choroidal neovascularization secondary to angioid streaks.
    Sawa M, Gomi F, Tsujikawa M, Sakaguchi H, Tano Y.
    Am J Ophthalmol; 2009 Oct; 148(4):584-590.e2. PubMed ID: 19541288
    [Abstract] [Full Text] [Related]

  • 5. Results of 1-year follow-up examinations after intravitreal bevacizumab administration for idiopathic choroidal neovascularization.
    Inoue M, Kadonosono K, Watanabe Y, Sato S, Kobayashi S, Yamane S, Ito R, Arakawa A.
    Retina; 2010 May; 30(5):733-8. PubMed ID: 20168271
    [Abstract] [Full Text] [Related]

  • 6. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF, Fromow-Guerra J, Sanchez JG, Maia M, Berrocal MH, Wu L, Saravia MJ, Costa RA, Pan-American Collaborative Retina Study Group.
    Retina; 2008 May; 28(10):1387-94. PubMed ID: 18827735
    [Abstract] [Full Text] [Related]

  • 7. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A.
    Retina; 2007 May; 27(4):432-8. PubMed ID: 17420694
    [Abstract] [Full Text] [Related]

  • 8. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin.
    Chan WM, Lai TY, Liu DT, Lam DS.
    Am J Ophthalmol; 2007 Jun; 143(6):977-983. PubMed ID: 17459318
    [Abstract] [Full Text] [Related]

  • 9. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results.
    Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB.
    Am J Ophthalmol; 2009 Jan; 147(1):84-93.e1. PubMed ID: 18774547
    [Abstract] [Full Text] [Related]

  • 10. Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization in ocular histoplasmosis.
    Hu J, Hoang QV, Chau FY, Blair MP, Lim JI.
    Retin Cases Brief Rep; 2014 Jan; 8(1):24-9. PubMed ID: 25372202
    [Abstract] [Full Text] [Related]

  • 11. Bevacizumab for choroidal neovascularization related to inflammatory diseases.
    Kramer M, Axer-Siegel R, Jaouni T, Reich E, Hemo I, Priel E, Averbukh E, Ehrlich R, Chowers I, Weinberger D, Amer R.
    Retina; 2010 Jun; 30(6):938-44. PubMed ID: 20168273
    [Abstract] [Full Text] [Related]

  • 12. Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to ocular histoplasmosis syndrome.
    Nielsen JS, Fick TA, Saggau DD, Barnes CH.
    Retina; 2012 Mar; 32(3):468-72. PubMed ID: 21817958
    [Abstract] [Full Text] [Related]

  • 13. Long-term visual outcomes of intravitreal bevacizumab in inflammatory ocular neovascularization.
    Mansour AM, Arevalo JF, Ziemssen F, Mehio-Sibai A, Mackensen F, Adan A, Chan WM, Ness T, Banker AS, Dodwell D, Chau Tran TH, Fardeau C, Lehoang P, Mahendradas P, Berrocal M, Tabbarah Z, Hrisomalos N, Hrisomalos F, Al-Salem K, Guthoff R.
    Am J Ophthalmol; 2009 Aug; 148(2):310-316.e2. PubMed ID: 19427992
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Macular functional changes evaluated with MP-1 microperimetry after intravitreal bevacizumab for subfoveal myopic choroidal neovascularization: one-year results.
    Scupola A, Tiberti AC, Sasso P, Savastano MC, Mastrocola A, Marangoni D, Minnella AM, Falsini B, Balestrazzi E.
    Retina; 2010 May; 30(5):739-47. PubMed ID: 20038860
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.